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and heart involvement – 1 (2.4%) patient.  Although in our cohort all the patients had lung 
involvement, only 18 (41%) of them needed corticosteroid treatment for pulmonary lesions. 
Detecting other organs affected by sarcoidosis imposed corticosteroid treatment for other 11 
(26.8%) patients  
Conclusions. Extrapulmonary lesions in sarcoidosis in our study group was a common finding, 
seen in more than a half of patients with pulmonary sarcoidosis. The most frequent 
extrapulmonary manifestion was the skin lesions seen in about 1/3 of patients. Recognizing 
extrapulmonary organs affected by sarcoidosis, indicating signs of organ damage, changed the 
management plan in almost a quarter of patients.  
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Introduction. Obstructive sleep apnoea (OSA) is highly prevalent and there is considerable 
evidence supporting an independent association with a wide range of co-morbidities including 
cardiovascular, endocrine and metabolic, neuropsychiatric, pulmonary, and renal.  
Aim of the study. The objective of this study is to assess the prevalance of major comorbidities 
associated with obstructive sleep apnea (OSA) and to examine the predictive role of Charlson 
comorbidity index (CCI) on mortality of patients with OSA associated with comorbidities.  
Materials and methods. This is a cross-sectional study of 67 patients diagnosed with OSA 
based on antropometric dates,cardiorespiratory polygraphy and AHI.Inclusion criteria were 
patients with diagnosis of OSA, who were aged 18 and above and had comorbidities.  We 
assess patients with comorbodities through Charlson index adapted to International 
Classification of Disease (ICD-10) codes.  Charlson Comorbidity Index (CCI) (Charlson et al., 
1987) quantifies an individual’s burden of disease and corresponding 1-year mortality risk.  
Each comorbidity category has an associated weight (from 1 to 6), based on the adjusted risk 
of mortality or resource use, and the sum of all the weights results in a single comorbidity score 
for a patient. A score of zero indicates that no comorbidities were found. The higher the score, 
the more likely the predicted outcome will result in mortality or higher resource use.  
Results. We evaluated 67 patients with OSA (51 men and 16 women) with a mean age of 53.9 
years (range 25–76 years). The prevalence of comorbidities were: hypertension (91%), obesity 
(85%), congestive heart failure (65%), pulmonary hypertension (26%), diabetes mellitus 
(25%), coronary heart disease (22%), etc. Based on the Charlson index of comorbidity the 
weighted index of comorbidity were: 0 for 6 patients, 1 for 17 patients,2 for 13 patients,3 for 
13 patients,4 for 11 patients, 5 for 5 patients and 6 for 2 patients. Combined condition and age-
related score were: 0 for 2 patients,1 for 8 patients,2 for 10 patients, 3 for 12 patients,4 for 9 
patients,5 for 8 patients,6 for 10 patients.7 for 1 patient and 8 for 1 patient.Patients with 
combined condition and age related score of 0 (2) estimated 10 year survival was 98 %, 1 (8) 
was 96%, 2 (10) was 90 %,3(12) was 77 %, 4 (9) was 53 %, 5 (9) was 21 %,6 was 2 %,7 was 
0 %,8 was 0 %.  
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Conclusions. Our study revealed that exists a strength association between 10 year survival 
rate and other two factors: age related score and weighted index of comorbidity.The 
cardiovascular diseases are the most predominant comorbidities at OSA patients.The patients 
with higher CCI scores had higher risk of mortality. The impact of comorbidities on the 
obstructive sleep apnea is significant. 
Key words: Obstructive sleep apneea(OSA), Comorbidity, Charlson index of 
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Introduction. Interstitial lung diseases (ILD) are a group of disorders that are generally 
thought to share a common pattern of physiologic abnormality characterized by a restrictive 
ventilatory defect and reduced diffusing capacity (DLCO). 
Aim of the study. To find distinctive features of the pulmonary function tests results in 
different types of ILD. 
Materials and methods. We have analyzed the data collected from 40 consecutive patients 
admitted to the Institute of Pthisiopneumology, Chisinau, Republic of Moldova, during January 
2019 – February 2020. We have included patients with ILD that are different from a 
morphological and pathogenetical point of view and distributed the patients as follows: 
Sarcoidosis patients – 10 cases, Idiopathic pulmonary fibrosis (IPF) patients – 8 cases, 
Nonspecific Idiopatic Insterstitial pneumonia (NSIP) patients – 7 patients, Hypersensitivity 
pneumonitis (HP) patients – 9 subjects and 6 Histiocytosis (Hx) cases. All patients have been 
evaluated by pulmonary function tests, 6MWT, Sa02, MRC scale for dyspnea, etc.  
Results. The mean age was 58.95 ±14.1 years, having the oldest patients (mean 69.7 ±8.3 
years) in the IPF subgroup, and the youngest in the Hx group (mean 38.3±15.6 years), p ˂ 0.001. 
The majority of patients were women (55%), and non-smoker patients (75%). Overall, the 
sarcoidosis and HP patients were 100% non-smokers, while all Hx patients were ever-smokers, 
p ˂0.001. The MRC dyspnea score median was 3 [2;3]. When compared by subgroups, the 
degree of dyspnea in sarcoidosis and in Hx patients was similar (p˃0.05). Moreover, IPF 
patients expressed significantly more dyspnea when compared to Sarcoidosis (p=0.01), or the 
Hx subgroup (p=0.025). Similarly, HP patients complained of more severe dyspnea when 
compared to sarcoidosis patients (p=0.029). In terms of pulmonary function tests we found 
normal mean FEV1 and FVC values (80.7±21.7 and 78.4±21.5 respectively), a slightly 
increased mean RV (127.5±42.1), a mildly decreased mean TLC (88.8±22.3) and a moderately 
decreased DLCO (52.6±21.5). Analyzing PFT parameters within the subgroups we found a 
predominant restrictive pattern, when defined as FEV1/FVC above 80%, in more than 70% of 
patients from all the subgroups. But when we applied the bodyplethismographic parameters, 
we have found that an air-trapping pattern, defined as an elevated RV combined with a normal 
TLC was identified in about 40% cases of patients with Hx, HP and sarcoidosis. 
